Abstract:Background: Over the past two decades, the Food and Drug Administration (FDA) has significantly increased the approval of anti−obesity medications (AOMs) for obesity management. Both FDA−approved AOMs (F−AOMs) and off−label AOMs (O−AOMs) have gained popularity and demonstrated promising results in randomized clinical trials (RCTs). However, their effectiveness in real−world settings remains less understood. In this study, we evaluated population−level responses to AOMs and individual variability under real−world conditions, leveraging electronic health records (EHRs) as the primary data source for a comprehensive analysis of obesity relevant metrics. Methods: EHRs of patients with obesity or overweight diagnosis were retrieved from the University of Texas Physician (UT−Physician) and EPIC COSMOS database. F−AOMs and O−AOMs were analyzed for their effects on obesity relevant metrics including body weight, body mass index (BMI), blood pressure (BP), high−density lipoprotein (HDL), low−density lipoprotein (LDL), HbA1c, and triglyceride levels. Results: From the UT−Physician (U) and COSMOS (C) datasets, we identified 444K (2005−2023) and 30M (2018−2023) patients as obese or overweight, respectively. Of these, 72,089 (6.2%) and 10M (~30%) had exposure to AOMs. During the study period, [U:37%; C:48%] of patients underwent more than one treatment session. The median exposure time to F−AOMs are [U:2.9; C:6.1] months. The median exposure time to O−AOMs are [U:2.9; C:14] months. For both cohorts, F−AOMs generally showed superior weight loss effects than O−AOMs. Tirzepatide and semaglutide were the most effective F−AOMs. Tirzepatide achieved 5% and 10% weight loss respectively in [U:65%; C:63%] and [U:33%; C:42%] of patients on long−term [U:76 wks; C:79 wks] exposure. Semaglutide achieved 5% and 10% weight loss respectively in [U:37%; C:45%] and [U:16%; C:25%] of patients on long−term [U:94 wks; C:88 wks] exposure. Both medications also benefited HDL, LDL, triglyceride, and HbA1c levels. Among O−AOMs, metformin demonstrated the most effective long−term [U:143 wks; C:166 wks] results, with [U:27%; C:32%] and [U:9%; C:14%] of patients achieving 5% and 10% weight loss, respectively. Significant individual variability in response was observed across all AOMs, irrespective of diagnosis type or exposure duration. Weight gain was noted in a subset of patients, ranging from [U:15%; C:18%] for tirzepatide (long−term) to [U:59%; C:62%] for lisdexamfetamine (long−term). Significant weight regain was consistently observed in both cohorts after discontinuing phentermine series, zonisamide, topiramate, and lisdexamfetamine. Conclusions: Remarkable differences were observed between real−world evidence from EHR data and RCT reports on AOM effectiveness, highlighting the challenges of applying RCT results to diverse populations in routine practice. The wide variation in individual responses to both FDA−approved and off−label AOMs underscores the importance of personalizing obesity treatment to improve effectiveness, support long−term adherence, and promote sustainable care strategies.

Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills

Current status of anti-obesity medications and performance, an EHR based survey

Access to Anti-Obesity GLP-1s for Medicare-Aged Adults

1684-P: CONCRETE—Characterization of Patients Receiving Telemedicine and Branded Antiobesity Medication for Medical Weight Management—A Retrospective Analysis

Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database

Primary care perspectives on prescribing anti-obesity medication for adolescents

The association between weight loss medications and cardiovascular complications

Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

The impact of approved anti-obesity medications on osteoarthritis

Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists

139-OR: An Obesity-centric Approach With and Without Antiobesity Medications Compared with the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting—A Pragmatic Randomized Controlled Trial (EMPOWER-T2D)

Demographic, Social, Behavioral, and Clinical Characteristics Associated with Long-Term Opioid Therapy and Any Opioid Prescription in High-Risk VA Patients

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

The contribution of obesity to prescription opioid use in the United States

Effectiveness and safety of drugs for obesity

Medications for Obesity: A Review

Racial Inequality in Receipt of Medications for Opioid Use Disorder

Frailty, Specialized Care, and Sociodemographic Factors: Disparities in Oral Pharmacotherapy Class Utilization Among Medicare Part D Beneficiaries With Overactive Bladder in the United States

Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity